Cryptogenic Stroke and Patent Foramen Ovale.

Area of Science:

• Cardiology
• Neurology
• Medical Devices

Background:

• Patent foramen ovale (PFO) is present in nearly half of cryptogenic stroke patients.
• The benefit of percutaneous PFO closure for secondary stroke prevention remains debated.
• Previous trials yielded inconclusive results on PFO closure efficacy.

Purpose of the Study:

• To clarify the role of transcatheter PFO closure in reducing recurrent cryptogenic stroke.
• To evaluate the long-term safety and efficacy of PFO closure versus medical therapy.
• To determine optimal patient selection criteria for PFO closure.

Main Methods:

• Analysis of long-term follow-up data from RESPECT trial.
• Inclusion of data from two new randomized trials: CLOSE and REDUCE.
• Comparison of transcatheter PFO closure with medical therapy in cryptogenic stroke patients.

Main Results:

• Transcatheter PFO closure significantly reduces the risk of recurrent stroke.
• Effective secondary prevention is achieved with appropriate patient selection.
• No increased risk of serious adverse events or major bleeding was observed.

Conclusions:

• Transcatheter PFO closure is a safe and effective strategy for secondary stroke prevention.
• Careful patient selection is crucial for maximizing the benefits of PFO closure.
• PFO closure should be considered in cryptogenic stroke patients with PFO.